MYC and breast carcinoma: Moreover, PKM2 was found to be upregulated in tamoxifen-resistant breast cancer cells, and depletion of PKM2 reversed tamoxifen resistance of breast cancer cells through a PKM2-c-MYC-Survivin pathway [53].